Among the patients who did not achieve complete remission after CAR-T-cell therapy for R/R DLBCL, the top ten genes with the highest mutation frequencies were TP53(41%), TTN(36%), BCR(27%), KMT2D(27%), IGLL5(23%), KMT2C(23%), MYD88(23%), BTG2(18%), MUC16(18%), and SGK1(18%). Here, BTG2 is linked to diffuse large B-cell lymphoma.